Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients
| العنوان: | Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients |
|---|---|
| المؤلفون: | Yara Banz, Urban Novak, Beatrice U. Mueller, Ulrike Bacher, Thomas Pabst, Bianca R Schnell, Katja Seipel, Barbara Jeker |
| المصدر: | HemaSphere Schnell, Bianca R.; Seipel, Katja; Bacher, Ulrike; Jeker, Barbara; Mueller, Beatrice U.; Banz, Yara; Novak, Urban; Pabst, Thomas (2019). Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients. HemaSphere, 3(2), e180. Wolters Kluwer Health 10.1097/HS9.0000000000000180 <http://dx.doi.org/10.1097/HS9.0000000000000180Test> HemaSphere, Vol 3, Iss 2 (2019) |
| بيانات النشر: | Wolters Kluwer Health, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | inorganic chemicals, medicine.medical_specialty, NPM1, Thrombocytosis, business.industry, lcsh:RC633-647.5, Megakaryocyte differentiation, Induction chemotherapy, Myeloid leukemia, 610 Medicine & health, Hematology, lcsh:Diseases of the blood and blood-forming organs, medicine.disease, Gastroenterology, Article, Internal medicine, medicine, 570 Life sciences, biology, Platelet, business, Thrombopoietin, Megakaryopoiesis |
| الوصف: | Whereas the molecular events underlying acute myeloid leukemia (AML) are increasingly identified, dynamics of hematologic recovery following induction chemotherapy remain mysterious. Platelet recovery may vary between incomplete and excess recovery among patients achieving remission. We analyzed platelet recovery after the first induction cycle in 291 consecutive AML patients. We defined excess platelet rebound (EPR) as platelet increase above 500 G/L. We observed EPR in 120 (41.2%) patients. EPR+ patients had lower platelets at diagnosis, higher marrow infiltration, more frequently NPM1 mutations, and were associated with ELN favorable risk. Absence of EPR correlated with complex karyotypes, ELN intermediate-I and adverse risk, and therapy-related AML. Overall survival was better in EPR+ patients than EPR- (median 125 vs 41 months; p = 0.04), as was disease-free survival. By multivariate analysis, EPR+ was an independent parameter associated with favorable survival. Plasma thrombopoietin (TPO) levels at diagnosis indicated EPR+ (p |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2572-9241 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edcbfaa14c6b285f3d9eaaaf27171dc3Test http://europepmc.org/articles/PMC6746035Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....edcbfaa14c6b285f3d9eaaaf27171dc3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 25729241 |
|---|